Clinical Trial Detail

NCT ID NCT01138085
Title Safety, Pharmacokinetics (PK) of AKT and MEK Combination
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors GlaxoSmithKline
Indications

Advanced Solid Tumor

Therapies

Trametinib + Uprosertib

Age Groups: adult

Additional content available in CKB BOOST